Skip to main content
Premium Trial:

Request an Annual Quote

R&D, Ruh-Roh

Pharmaceutical companies are watching their R&D costs go up, up, up, as they search for the next blockbuster drug amid dried-up pipelines and upcoming patent cliffs, reports The Guardian's Julia Kollewe. A recent Deloitte report shows that the cost of bringing a drug to market for the world's 12 biggest pharma companies has risen by more than 25 percent to about $1 billion this year from about $830 million in 2010, Kollewe says. Meanwhile, the number of late-stage drugs in development has dropped from 23 to 18 per company on average, she adds.

In the meantime, Pharmalot's Ed Silverman says returns on R&D investments are falling sharply. The same Deloitte report says that 10 out of the 12 companies surveyed show a decline of about 29 percent in their internal rate of return on R&D. "Specifically, the internal rate of return on R&D fell to 8.4 percent this year from 11.8 percent in 2010 from 8.4 percent the year before," Silverman says.

The Scan

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.

Genome-Wide Analysis Sheds Light on Genetics of ADHD

A genome-wide association study meta-analysis of attention-deficit hyperactivity disorder appearing in Nature Genetics links 76 genes to risk of having the disorder.

MicroRNA Cotargeting Linked to Lupus

A mouse-based study appearing in BMC Biology implicates two microRNAs with overlapping target sites in lupus.

Enzyme Involved in Lipid Metabolism Linked to Mutational Signatures

In Nature Genetics, a Wellcome Sanger Institute-led team found that APOBEC1 may contribute to the development of the SBS2 and SBS13 mutational signatures in the small intestine.